Immunohistochemistry no longer only names a tumour — increasingly, it chooses the drug. A membrane score gates an antibody–drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.
Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.
Markers covered: PD-L1 · HER2 and HER2-low/ultralow · MMR/MSI · ER, PR and Ki-67 · Trop-2 · Nectin-4 · FRα · Claudin 18.2 · HER3 · B7-H3 · quantitative and AI-assisted scoring.
Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.
Written for practising pathologists, trainees, and tumour-board participants.
Expression is not eligibility.
"Sinopsis" puede pertenecer a otra edición de este libro.
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. pp. 600. Nº de ref. del artículo: 7557530
Cantidad disponible: 4 disponibles
Librería: Books Puddle, Woodside, NY, Estados Unidos de America
Condición: New. pp. 600 Index. Nº de ref. del artículo: 26323141
Cantidad disponible: 4 disponibles
Librería: Biblios, Frankfurt am main, HESSE, Alemania
Condición: New. pp. 600. Nº de ref. del artículo: 18323151
Cantidad disponible: 4 disponibles
Librería: California Books, Miami, FL, Estados Unidos de America
Condición: New. Nº de ref. del artículo: I-9788190322805
Cantidad disponible: Más de 20 disponibles
Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de America
Paperback. Condición: new. Paperback. Immunohistochemistry no longer only names a tumour - increasingly, it chooses the drug. A membrane score gates an antibody-drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.Markers covered: PD-L1 - HER2 and HER2-low/ultralow - MMR/MSI - ER, PR and Ki-67 - Trop-2 - Nectin-4 - FRa - Claudin 18.2 - HER3 - B7-H3 - quantitative and AI-assisted scoring.Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.Written for practising pathologists, trainees, and tumour-board participants.Expression is not eligibility. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Nº de ref. del artículo: 9788190322805
Cantidad disponible: 1 disponibles
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de America
PAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Nº de ref. del artículo: L0-9788190322805
Cantidad disponible: Más de 20 disponibles
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
PAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Nº de ref. del artículo: L0-9788190322805
Cantidad disponible: Más de 20 disponibles
Librería: CitiRetail, Stevenage, Reino Unido
Paperback. Condición: new. Paperback. Immunohistochemistry no longer only names a tumour - increasingly, it chooses the drug. A membrane score gates an antibody-drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.Markers covered: PD-L1 - HER2 and HER2-low/ultralow - MMR/MSI - ER, PR and Ki-67 - Trop-2 - Nectin-4 - FRa - Claudin 18.2 - HER3 - B7-H3 - quantitative and AI-assisted scoring.Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.Written for practising pathologists, trainees, and tumour-board participants.Expression is not eligibility. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Nº de ref. del artículo: 9788190322805
Cantidad disponible: 1 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Taschenbuch. Condición: Neu. Neuware - Immunohistochemistry no longer only names a tumour - increasingly, it chooses the drug. A membrane score gates an antibody-drug conjugate; a percentage of stained nuclei opens or closes a line of therapy; a pattern of nuclear loss unlocks immunotherapy across the body.Yet the threshold that decides treatment is not a fact about the tumour. It is a decision rule tied to a particular trial, a particular drug, and a particular assay. For every predictive marker, this pan-tumour guide sets out what to score, where the cutoff came from, how reproducibly it can be read, and how to report it in language the oncologist can act on.Markers covered: PD-L1 - HER2 and HER2-low/ultralow - MMR/MSI - ER, PR and Ki-67 - Trop-2 - Nectin-4 - FRa - Claudin 18.2 - HER3 - B7-H3 - quantitative and AI-assisted scoring.Inside this edition: fifteen focused chapters across four parts; the trial-validated cutoff behind every marker; reproducibility and the faint-end problem, marker by marker; pitfalls at the bench, controls, and external quality assurance; assay, clone and platform specifics throughout; and synoptic reporting templates.Written for practising pathologists, trainees, and tumour-board participants.Expression is not eligibility. Nº de ref. del artículo: 9788190322805
Cantidad disponible: 2 disponibles